Recently in Science Translational Medicine, Bagó et al. reported an advance in treating glioblastoma using tumor-homing cytotoxic induced neural stem cells (h-iNSCTE). This approach circumvents problems associated with immune rejection and minimizes the bench-to-clinic time window critical for these patients.